share_log

Cartesian Therapeutics' Approximately $104.8M Of Cash, Cash Equivalents, And Restricted Cash As Of March 31, 2024, Expected To Support Planned Operations Into 2H 2026

Benzinga ·  May 8 07:22
Cartesian Therapeutics' Approximately $104.8M Of Cash, Cash Equivalents, And Restricted Cash As Of March 31, 2024, Expected To Support Planned Operations Into 2H 2026
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment